Pfizer registers Phase 3 marstacimab hemophilia trial and elranatamab myeloma comparison study

Pfizer registered two studies on November 9, 2026, spanning a Phase 3 interventional trial and an observational comparative study.

• A Phase 3 trial of marstacimab (PF-06741086) in mild to moderate hemophilia A or B without inhibitors is recruiting. The open-label, multicenter study is evaluating efficacy and safety of marstacimab prophylaxis in approximately 95 male and female adolescents and adults aged 12 to under 75 years with mild to moderate hemophilia A or B without inhibitors who have a severe bleeding phenotype.¹ The study compares bleeding outcomes during a historical 12-month period of factor replacement therapy with outcomes during a 12-month treatment phase in which participants receive marstacimab 150 mg subcutaneously once weekly.¹
• An observational study comparing elranatamab monotherapy against real-world standard-of-care therapy for relapsed/refractory multiple myeloma is not yet recruiting. The study will use data from the Phase 3 MagnetisMM-5 trial for elranatamab and from a real-world database representing standard-of-care clinical practice.² The study is not seeking any participants for enrollment.² Primary completion is estimated for February 1, 2027.